Analyst reports.
This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.
Analyst Reports 2022
Analyst Reports 2022
December 14th 2022
Bell Potter - Analyst Outlook & Stock Picks for 2023
December 5th 2022
Jefferies - Immutep (IMM AU, BUY): Expanding into Urothelial Cancer (Analyst: Dr David Stanton)
November 29th 2022
CLSA Equity Research - Immutep (IMM) announces a new collaboration with Merck KGaA and Pfizer for a Ph 1 clinical trials for metastatic urothelial cancer (INSIGHT-005) (ASX:IMM) (Analyst: Andrew Paine)
November 29th 2022
Petra Capital - Immutep Limited (IMM) - New clinical trial collaboration with Merck KGaA/Pfizer for Phase 1 with efti in urothelial cancer, a positive with more to come (Analyst: Tanushree Jain)
November 16th 2022
Petra Capital - Immutep Limited (IMM) - Stellar NSCLC showing at SITC, registrational trial in 2H23 (Analyst: Tanushree Jain)
November 11th 2022
Ladenburg Thalmann - SITC: Efti Is Active in NSCLC, Adaptive Registration Trial Is Next; Reaffirm Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
November 11th 2022
CLSA Equity Research - Unrealised value - Lung data update supportive of overall value realisation into CY23 (ASX:IMM) (Analyst: Andrew Paine)
November 10th 2022
Jefferies - IMM AU Releases Positive SITC Data (ASX: IMM) (Analyst: Dr David Stanton)
November 10th 2022
Maxim Group - Efti in 1L Lung Cancer at SITC – Response Rates are Favorable, but it's the Duration of Response that Impresses (Analyst: Jason McCarthy)
November 7th 2022
Maxim Group - Late-Breaking Abstract for Eftilagimod Selected for SITC Press Conference (Analyst: Jason McCarthy)
October 26th 2022
Ladenburg Thalmann - NSCLC Is the Focus for Late-stage Development; Reiterate Buy and $8.30 PT (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
October 25th 2022
Petra Capital - Immutep Limited (IMM) - TACTIcal IO Positioning - Hard to Ignore; Initiating with Buy rating and A$1.19 Target (Analyst: Tanushree Jain)
October 6th 2022
CLSA Equity Research - PD-L1 competition good for efti - GSK’s PD-L1 result highlights increasing competition for Keytruda (ASX:IMM) (Analyst: Andrew Paine)
October 5th 2022
Maxim Group - Looking Towards SITC In November; Eftilagimod Abstracts Accepted (Analyst: Jason McCarthy)
October 4th 2022
CLSA Equity Research - Tracking positively - FDA NSCLC Fast Track designation follows promising data readout (ASX:IMM) (Analyst: Andrew Paine)
September 5th 2022
CLSA Equity Research - Immutep : On to the main acts (ASX:IMM) (Analyst: Andrew Paine)
August 31st 2022
CLSA Equity Research - Immutep FY22 Result: Cash runway to early-CY24; may prioritise 1L NSCLC trial (which is in combo with Keytruda) (ASX:IMM) (Analyst: Andrew Paine)
August 31st 2022
Jefferies - Immutep Ltd | BUY : IMM AU | AUD0.29 | PT: AUD1.00 (AUD0.90) | % to PT: +245% - FY22: Run (ASX: IMM) (Analyst: Dr David Stanton)
August 2nd 2022
Maxim Group - Interim Data from TACTI-002 Study to be Presented at World Conference on Lung Cancer, Aug 6-9 (Analyst: Jason McCarthy)
August 1st 2022
Ladenburg Thalmann - One Drug, Multiple Late-stage Opportunities; Reiterate Buy Rating (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
July 22nd 2022
Jefferies - IMM AU - Increased Importance of TACTI-003 for MRK in HNSCC (ASX: IMM) (Analyst: Dr David Stanton)
June 7th 2022
CLSA Equity Research - Not Lag-ging - Ph2 data support progression to Ph3 on positive results (ASX:IMM) (Analyst: Andrew Paine)
June 7th 2022
Bell Potter - IMM - a very viable big pharma target (Analyst: Dr Tara Speranza)
June 6th 2022
Maxim Group - Positive 1L Lung Cancer Data for Efti/Pembro at ASCO; Webcast Today at 6pm ET (Analyst: Jason McCarthy)
June 4th 2022
Jefferies - IMM AU releases ASCO Data (ASX: IMM) (Analyst: Dr David Stanton)
May 27th 2022
CLSA Equity Research - Another promising readout - 1L NSCLC readout shows slight increase in ORR in larger patient cohort (ASX:IMM) (Analyst: Andrew Paine)
May 12th 2022
Maxim Group - Disappointing Data for TIGIT; Nice Set up for Immutep’s soluble LAG-3 in 1L NSCLC? ASCO is Next (Analyst: Dr Naureen Quibria)
May 5th 2022
CLSA Equity Research - Raising the profile - AIPAC data continues to support MOA ahead of key conference (ASX:IMM) (Analyst: Andrew Paine)
May 5th 2022
Bell Potter - Breast cancer trial data supports mechanism of action (Analyst: Dr Tara Speranza)
March 25th 2022
Ladenburg Thalmann - ELCC Abstract: First Data in 2L NSCLC from TACTI-002; Reiterate Buy (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
March 24th 2022
Jefferies - New TACTI-002 Data - Efficacy in Line, SE Lower (ASX: IMM) (Analyst: Dr David Stanton)
March 24th 2022
CLSA Equity Research - Keep on keeping on - 2L NSCLC within expectations, but 1L HNSCC & NSCLC remain focus (ASX:IMM) (Analyst: Andrew Paine)
March 21st 2022
Ladenburg Thalmann - The Key Approval Arrived in the LAG-3 Arena (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)
March 20th 2022
CLSA Equity Research - LAG-3 launch pad - FDA approval of LAG-3 therapy a key milestone for the sector (ASX:IMM) (Analyst: Andrew Paine)
March 19th 2022
Jefferies - First LAG-3 Checkpoint Inhibitor Approved (ASX: IMM) (Analyst: Dr David Stanton)
March 1st 2022
CLSA Equity Research - Hitchin’ a ride - BMS’ LAG-3 FDA approval could see increased interest in I-O sector (ASX:IMM) (Analyst: Andrew Paine)
February 23rd 2022
Maxim Group - Reports Half-Year Results; Eyeing the First External LAG-3 Approval from Bristol (Analyst: Dr Naureen Quibria)
January 31st 2022